Originally published on March, 2024
**Updated as of August 2025**
If you were previously trying to get Mounjaro but were not able to find it at a pharmacy, it can be frustrating. We are here to help you understand the most up-to-date information on the supply of Mounjaro in Canada.
Is there currently a Mounjaro shortage in Canada?
Mounjaro first became available in Canada in November 2023, but the initial supply of the vial format was very limited, leading to a shortage. This shortage was resolved by late 2024 to early 2025. However, supply of the vials became tight again in mid-2025, and they are once more being reported as in shortage. In contrast, the Mounjaro KwikPen was introduced in May 2025 and has remained widely available across Canada. At this time, patients can access Mounjaro through the KwikPen format, while the vial format continues to face recurring shortages.
Why was there currently a shortage of Mounjaro?
A shortage usually occurs when there isn’t a stable supply of a particular medication, and pharmacies are unable to order required quantities from their distributors. When shipments do arrive, they arrive unpredictably. As a result, the inventories at a pharmacy can vary week from week. In many cases, pharmacies will have no supply at all.
The shortage of Mounjaro in Canada was previously driven by very high consumer and patient demand. As a brand name drug, Mounjaro can only be manufactured by Eli Lilly & Company, which holds the patent for these medications. While working to ramp up manufacturing capacity, Eli Lilly was unable to keep up with the growth in demand for this medication around the world, including in Canada.
However, now with the introduction of Mounjaro Kwikpen, a steady supply of the medication is available throughout Canada.
When will the shortage for Mounjaro vials be over?
Mounjaro vial shortages are expected to persist at this time as the supply of Mounjaro Kwikpen is being prioritized. This is based on information from the manufacturer, and may be updated at a later time.
How is Cloudcure helping patients during this shortage period?
While there is currently a shortage of Mounjaro vials in Canada, the Mounjaro KwikPen is widely available as a direct alternative. However, the KwikPen can be more expensive, so the main challenge for many patients sometimes is not supply but access and cost.
To help with this, Cloudcure supports patients in enrolling in patient assistance programs such as myMounjaro and myZepbound, which may reduce the financial burden and improve access to treatment. Our medical team also works with patients to explore other effective treatment options, including Wegovy, Ozempic, Zepbound, and more than 10 additional therapies for obesity that are not currently facing shortages in Canada.
Cloudcure’s goal is to make sure patients continue to receive safe, effective care without interruption — whether through assistance programs, alternative formats, or other available treatments.
Key Take-Aways
-
No true nationwide shortage: While Mounjaro vials remain in short supply, the Mounjaro KwikPen is widely available across Canada. The main barrier for patients is often cost and access, since the KwikPen is more expensive than the vial.
-
Cloudcure can help with access: We help patients sign up for myMounjaro and myZepbound assistance programs, which can reduce costs and make treatment more affordable.
- No true nationwide shortage: While Mounjaro vials remain in short supply, the Mounjaro KwikPen is widely available across Canada. The main challenge for many patients is access and affordability, as the KwikPen can be more costly than the vial format.
- Alternatives for weight loss medications are available: In addition to Mounjaro, Cloudcure prescribes a wide range of safe and effective treatments, including Wegovy, Zepbound, Ozempic, and over 10 additional therapies for obesity that are not currently experiencing shortages in Canada.
- Continuity of care matters: If you’re starting or continuing treatment, it’s important to consider supply stability. Cloudcure’s medical team can guide you to the most suitable option to avoid treatment interruptions and ensure lasting results.
